natgillin/translations-raw huggingface dataset:
The study compared 25 mg Torisel with interferon alfa (another anticancer medicine) and with 15 mg Torisel in combination with interferon alfa.
V študiji so primerjali učinek 25-miligramskega odmerka zdravila Torisel z učinkom interferona alfa (drugega zdravila proti raku) in z učinki 15-miligramskega odmerka zdravila Torisel v kombinaciji z interferonom alfa.
The study compared Avastin with placebo when given in combination with interferon alfa-2a.
V študiji so zdravilo Avastin primerjali s placebom, pri čemer so oba kombinirali z jemanjem interferona alfa-2a.
The study compared how long patients survived when Tarceva was used early in the study with how long they survived when Tarceva was used later in the study. the fourth study involved 731 patients who had not responded to at least one previous chemotherapy treatment; this study compared Tarceva to placebo.
V študiji so čas preživetja bolnikov, kadar se je zdravilo Tarceva uporabilo na začetku študije, primerjali z rezultati njihovega preživetja, kadar se je to zdravilo uporabilo kasneje v študiji; v četrto študijo je bilo vključenih 731 bolnikov, ki se niso odzvali na vsaj eno predhodno zdravljenje s kemoterapevtiki; v tej študiji so zdravilo Tarceva primerjali s placebom.
The study compared Imnovid plus low-dose dexamethasone with high-dose dexamethasone alone.
V študiji so zdravilo Imnovid v kombinaciji z nizkoodmernim deksametazonom primerjali s samostojnim visokoodmernim deksametazonom.
The study compared Ixiaro with another vaccine for Japanese encephalitis containing viruses grown in mouse brains.
V študiji so cepivo Ixiaro primerjali z drugim cepivom proti japonskemu encefalitisu, ki je vsebovalo viruse, gojene v mišjih možganih.
The study compared lenalidomide in combination with melphalan and prednisone (MPR) with or without lenalidomide maintenance monotherapy until disease progression, to that of melphalan and prednisone for a maximum of 9 cycles.
V študiji so primerjali lenalidomid v kombinaciji z melfalanom in prednizonom (MPR) z vzdrževalno monoterapijo z lenalidomidom do napredovanja bolezni ali brez nje, z melfalanom in prednizonom za največ 9 ciklov.
The study compared Raplixa used with the gelatin sponge, with the gelatin sponge used on its own.
V študiji so zdravilo Raplixa, uporabljeno z želatinsko gobico, primerjali z uporabo želatinske gobice same.
The study compared the ability of the two vaccines to trigger the production of antibodies (immunogenicity), by comparing antibody levels before injection and three weeks afterwards.
V študiji so primerjali učinkovitost obeh cepiv pri sprožanju tvorjenja protiteles (imunogenost), tako da so primerjali ravni protiteles pred injiciranjem in tri tedne po njem.
The study compared the effect of melphalan and prednisone, with or without Thalidomide Celgene, on survival times.
V študiji so primerjali učinek melfalana in prednizona v kombinaciji z zdravilom Thalidomide Celgene oziroma brez njega na čas preživetja bolnika.
The study compared the effectiveness of switching to Atripla tablets, taken on an empty stomach, with that of remaining on the successful HIV treatment combination.
V študiji so primerjali učinkovitost prehoda na tablete Atripla, vzete na prazen želodec, v primerjavi z nadaljevanjem jemanja učinkovite kombinacije zdravil.
The study compared the effects of adding Inovelon tablets or adding placebo (a dummy treatment) to the other medicines the patients were taking.
V študiji so primerjali učinke dodajanja zdravila Inovelon v tabletah ali dodajanja placeba (zdravila brez zdravilne učinkovine) k zdravljenju z drugimi zdravili, ki so jih bolniki že jemali.
The study compared the effects of replacing lamivudine with Emtriva, or remaining on the existing antiviral medicine combination.
V študiji so primerjali učinke pri zamenjavi lamivudina z zdravilom Emtriva z učinki, ki so jih opazili pri bolnikih, ki so ostali pri stari kombinaciji protivirusnih zdravil.
The study compared the efficacy of olaparib maintenance treatment taken until progression with no maintenance treatment in 265 (136 olaparib and 129 placebo) PSR serous ovarian cancer patients who were in response (CR [complete response] or PR [partial response]) confirmed as per RECIST and/or as per CA-125 criteria as defined by Gynecologic Cancer InterGroup (GCIG) (at least a 50% reduction in CA-125 levels from the last pre-treatment sample, confirmed 28 days later) following completion of two or more previous platinum containing chemotherapy.
Študija je primerjala učinkovitost vzdrževalnega zdravljenja z olaparibom, uporabljanim do napredovanja, z neuporabo kakršnega koli vzdrževalnega zdravljenja pri 265 bolnicah (136 olaparib in 129 placebo) s PSR seroznim rakom jajčnikov, ki so bile v odzivu (popolnem odzivu [CR – complete response] ali delnem odzivu [PR – partial response]) potrjenem po merilih RECIST in/ali po kriterijih vrednosti CA-125, kot jih opredeljuje GCIG (Gynecologic Cancer InterGroup) (vsaj 50 % zmanjšanje koncentracije CA-125 od zadnje meritve na vzorcu pred zdravljenjem, potrjeno 28 dni pozneje), po dokončanju dveh ali več predhodnih kemoterapij na osnovi platine.
The study compared the immune response of babies aged nine or 11 months at the time of the first dose with that of babies aged 12 months.
V študiji so primerjali imunski odziv dojenčkov, starih devet ali 11 mesecev, ob prvem odmerku, z odzivom dojenčkov, starih 12 mesecev.
The study compared the immunogenicity of the two vaccines against the different polysaccharides.
V študiji so primerjali imunogenost teh dveh cepiv proti različnim polisaharidom.
The study compared Tyverb alone with a combination of Tyverb plus trastuzumab.
V študiji so uporabo zgolj zdravila Tyverb primerjali s kombinacijo zdravila Tyverb in trastuzumaba.
The study compared Tyverb in combination with capecitabine, with capecitabine taken alone.
V študiji so zdravilo Tyverb v kombinaciji s kapecitabinom primerjali s kapecitabinom kot samostojnim zdravilom.
The study compared Tyverb with placebo (a dummy treatment), both of which were taken together with letrozole (an aromatase inhibitor).
V študiji so zdravilo Tyverb primerjali s placebom (zdravilom brez zdravilne učinkovine), pri čemer so bolnice oboje jemale v kombinaciji z letrozolom (zaviralcem aromataze).
The study Data Safety Monitoring Board stopped the ZDV/3TC/ABC arm at this time based on the higher proportion of patients with virologic failure.
V tem času je študijski odbor za spremljanje podatkov o varnosti zaradi visokega odstotka bolnikov z virološkim neuspehom prekinil zdravljenje v skupini, ki je prejemala ZDV/3TC/ABC.
The study demonstrated a clinically and statistically significant relative risk reduction of 18% in the rate of the primary composite endpoint of cardiovascular mortality and hospitalisation for worsening heart failure (hazard ratio: 0.82, 95%CI [0.75;0.90] – p<0.0001) apparent within 3 months of initiation of treatment.
Študija je dokazala klinično in statistično značilno relativno zmanjšanje tveganja za 18 % za primarni končni izid, sestavljen iz srčno-žilne umrljivosti in hospitalizacije zaradi poslabšanja srčnega popuščanja (razmerje tveganja: 0,82, 95 % interval zaupanja [0,75;0,90] - p<0,0001), vidnega po 3 mesecih po začetku zdravljenja.
The study demonstrated no effect on QT/QTc interval duration as well as any other ECG interval at doses up to 2.25 mg.
Študija ni pokazala nikakršnega učinka na trajanje intervala QT/QTc ali na kakšen drug EKG interval v odmerkih do 2,25 mg.
The study demonstrated that foetuses exposed in utero to the combination sustained a higher level of nucleoside analogue- DNA incorporation into multiple foetal organs, and showed evidence of more telomere shortening than in those exposed to zidovudine alone.
Raziskava je pokazala, da je pri fetusih, ki so bili in utero izpostavljeni kombinaciji prišlo do obširne vgraditve nukleozidnih analogov DNA v več organov fetusa in večjega skrajšanja telomer, kot pri tistih, ki so bili izpostavljeni samo zidovudinu.
The study demonstrated that the post-treatment recovery in growth at 2 years post-treatment was maintained to 6 years post-treatment.
Študija je dokazala, da se je izboljšanje rasti dve leti po zdravljenju ohranilo tudi do šest let po zdravljenju.
The study design was similar to study Harmony I except that the maximum dose for pitolisant reached by 75% of patients was 18 mg once a day instead of 36 mg in Harmony I. As an important unbalance led to comparison of results with or without cluster grouping of sites, the most conservative approach showed non-significant ESS score decrease with pitolisant compared to placebo (pitolisant-placebo=-1.94 with p=0.065).
Načrt študije je bil podoben študiji Harmony I, čeprav je bil največji odmerek pitolizanta, ki ga je doseglo 75 % bolnikov, 18 mg enkrat na dan namesto 36 mg pri študiji Harmony I. Ker je pomembno neravnovesje privedlo do primerjave rezultatov z razvrščanjem centrov v skupine oziroma brez tega razvrščanja, je najbolj konzervativni pristop pokazal statistično neznačilno zmanjšanje rezultata ESS pri pitolizantu v primerjavi s placebom (pitolizant- placebo = 1,94 z vrednostjo p = 0,065).
The study did not contain a control arm of patients not receiving Kaletra.
Raziskava ni obsegala kontrolnega kraka bolnikov brez zdravila Kaletra.
The study did not meet either primary objective of demonstrating a reduction in risk for all-cause mortality or cardiovascular morbidity (darbepoetin alfa vs placebo; HR 1.05, 95% CI (0.94, 1.17)), or all-cause mortality or end stage renal disease (ESRD) (darbepoetin alfa vs placebo; HR 1.06, 95% CI (0.95, 1.19)).
Študija ni izpolnila primarnega cilja, ki je bil dokazati zmanjšanje tveganja umrljivosti zaradi vseh vzrokov, kardiovaskularne obolevnosti (darbepoetin alfa in placebo; razmerje ogroženosti 1,05, 95 % IZ (0,94, 1,17)) ali tveganja umrljivosti zaradi vseh vzrokov ali končne odpovedi ledvic (darbepoetin alfa in placebo; razmerje ogroženosti 1,06, 95 % IZ (0,95, 1,19)).
The study did not meet either primary objective of demonstrating a reduction in risk for all-cause mortality, cardiovascular morbidity, or end stage renal disease (ESRD).
Študija ni dosegla primarnega cilja – dokazati zmanjšanje tveganja za splošno umrljivost, srčnožilno obolevnost ali končno ledvično odpoved (KLO).
The study did not meet its primary objective of demonstrating a reduction in risk of all-cause mortality or cardiovascular events including myocardial infarction, hospitalisation for unstable angina, heart failure or peripheral vascular event (HR 0.93; 95% CI: 0.85, 1.02; p = 0.112).
Študija ni dosegla primarnega cilja in sicer dokazanega zmanjšanja tveganja za umrljivost zaradi vseh vzrokov ali kardiovaskularnih dogodkov, vključno z miokardnim infarktom, hospitalizacijo zaradi nestabilne angine pektoris, srčnim popuščanjem ali perifernim žilnim dogodkom (razmerje ogroženosti 0,93, 95% interval zaupanja: 0,85, 1,02, p = 0,112).
The study efficacy results for these patients are summarised in Table 21.
Podatki učinkovitosti študije za te bolnike so povzeti v preglednici 21.
The study employed historical controls from the same centre as patients who received asfotase alfa and who had been subject to a similar protocol of clinical management.
V študiji so uporabljeni zgodovinski kontrolni podatki istega raziskovalnega centra, saj so bolniki, ki so prejemali asfotazo alfa, predmet podobnega protokola klinične obravnave.
The study enrolled 69 subjects in 5 groups: Group 1 enrolled 11 subjects who had previously received 2 doses of the A/Vietnam/1203/2004 H5N1 pandemic live attenuated influenza vaccine (P/LAIV) in 2006-2007; Group 2 enrolled 10 subjects who had previously received 2 doses of the A/Hong Kong/213/2003 H5N1 P/LAIV in 2007; Group 3 enrolled 8 subjects who had previously received 2 doses of the A/British Columbia/CN-6/2004 H7N3 P/LAIV in 2010 (as a P/LAIV control group); Groups 4 and 5 each enrolled 20 subjects who had not been previously vaccinated with LAIV and were influenza H5 naïve.
Študija je zajela 69 oseb v 5 skupinah: 1. skupina je vključila 11 preiskovancev, ki so predhodno dobili 2 odmerka pandemskega oslabljenega cepiva proti gripi A/Vietnam/1203/2004 H5N1 (P/LAIV) v letih 2006-2007, 2. skupina je vključila 10 preiskovancev, ki so predhodno dobili 2 odmerka A/Hong Kong/213/2003 H5N1 P/LAIV leta 2007, 3. skupina je vključila 8 preiskovancev, ki so predhodno dobili 2 odmerka A/British Columbia/CN- 6/2004 H7N3 P/LAIV leta 2010 (kot kontrolno skupino P/LAIV), 4. in 5. skupina pa sta vsaka vključili 20 preiskovancev, ki predhodno niso bili cepljeni z LAIV in so bili naivni za gripo H5.
The study enrolled a total of 123 previously treated male patients (12 to 71 years of age) with severe haemophilia B (≤ 2% endogenous FIX activity).
V študijo je bilo skupaj vključenih 123 predhodno zdravljenih bolnikov moškega spola (starih 12 do 71 let) s hudo hemofilijo B (≤ 2 % endogene aktivnosti FIX).
The study enrolled a total of 165 previously treated male patients (12 to 65 years of age) with severe haemophilia A. Subjects on prophylaxis regimens prior to entering the study were assigned to the individualised prophylaxis arm.
V študijo je bilo skupaj vključenih 165 predhodno zdravljenih bolnikov moškega spola (starih 12 do 65 let) s hudo hemofilijo A. Osebe na profilaktičnem režimu so bile pred vstopom v študijo dodeljene v individualiziran profilaktični krak.
The study enrolled patients on a stable but virologically failing antiretroviral treatment regimen, with a confirmed HIV-1 RNA plasma viral load
V študijo so bili vključeni bolniki, ki so prejemali stabilen, vendar virološko neuspešen režim zdravljenja in s potrjenim HIV-1 RNK plazemskim virusnim bremenom
The study enrolled patients with 4 to 8 clinically typical, visible, discrete non-hypertrophic and non-hyperkeratotic AK lesions within a 25 cm2 contiguous treatment area.
Študija je vključevala bolnike s 4 do 8 klinično tipičnimi, vidnimi, ločenimi nehipertrofičnimi in nehiperkeratoznimi lezijami zaradi aktinične keratoze na neprekinjenem predelu v velikosti 25 cm2.
The study enrolled women aged 55 to 80 years, who were at least 5 years postmenopausal, who had a BMD at the lumbar spine of -2 to -5 SD below the premenopausal mean (T-score) in at least one vertebra [L1-L4], and who had one to four prevalent vertebral fractures.
Študija je vključevala ženske, stare od 55 do 80 let, ki so bile vsaj 5 let po menopavzi in ki so imele MKG ledvene hrbtenice –2 do –5 SD pod povprečno vrednostjo pred menopavzo (T-vrednost) pri vsaj enem vretencu (L1–L4) ter so imele enega do štiri predhodnih zlomov vretenc.
The study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least one but no more than four disease-modifying antirheumatic drugs (DMARDs).
V študijo je bilo vključenih 234 odraslih bolnikov z aktivnim revmatoidnim artritisom, ki so bili pred tem neuspešno zdravljeni vsaj z enim, a ne več kot 4 imunomodulirajočimi antirevmatičnimi zdravili (DMARD – Disease-Modifying AntiRheumatic Drug).
The study evaluated the mean symptom score using the change from baseline to the end of treatment.
V študiji so ocenjevali povprečni izid simptomov, pri čemer so uporabili spremembo med izhodiščem in koncem zdravljenja.
The study excluded patients with autoimmune disease or those receiving immunosuppression; further exclusion criteria were a history of severe or life-threatening immune- related adverse reactions from treatment with ipilimumab, defined as any Grade 4 toxicity or Grade 3 toxicity requiring corticosteroid treatment (> 10 mg/day prednisone or equivalent dose) for greater than 12 weeks; ongoing adverse reactions ≥ Grade 2 from previous treatment with ipilimumab; previous severe hypersensitivity to other monoclonal antibodies; a history of pneumonitis or interstitial lung disease; HIV, hepatitis B or hepatitis C infection and ECOG Performance Status ≥ 2.
V študijo niso bili vključeni bolniki z avtoimunskimi boleznimi in bolniki, ki so prejemali imunosupresivno zdravljenje; dodatna merila za nevključitev so bila anamneza hudih ali življenjsko nevarnih imunsko pogojenih neželenih učinkov zaradi zdravljenja z ipilimumabom, kar je bilo opredeljeno kot kateri koli toksični učinek 4. stopnje ali toksični učinek 3. stopnje, ki je zahteval več kot 12 tedensko zdravljenje s kortikosteroidi (> 10 mg/dan prednizona ali ekvivalenta); še trajajoč neželen učinek ≥ 2. stopnje od predhodnega zdravljenja z ipilimumabom; predhodna huda preobčutljivost za druga monoklonska protitelesa; anamneza pnevmonitisa ali intersticijske bolezni pljuč; okužba s HIV, hepatitisom B ali hepatitisom C in telesna zmogljivost ≥ 2 po ECOG.
The study failed to meet the primary end point which was the clinical success rate at follow-up (day 12 – 14) for subjects in the Intent to Treat Clinical population (see Table below).
Študija ni dosegla primarne končne točke, ki je bila delež klinične uspešnosti med spremljanjem (od 12. do 14. dneva) pri preizkušancih v skupini, ki so jo nameravali zdraviti (glejte spodnjo tabelo).
The study followed an open-label, single arm, non-randomized design and included eligible subjects who had previously received cholic acid through CAC-91-10-10 and newly diagnosed subjects.
Študija je imela odprt, nerandomiziran načrt z eno skupino in je vključila primerne bolnike, ki so predhodno prejemali holno kislino v študiji CAC-91-10-10, in bolnike z novo postavljeno diagnozo.
The study had also an extension phase, in which all patients received Revolade.
Študija je obsegala tudi podaljšano fazo, v kateri so vsi bolniki jemali zdravilo Revolade.
The study in adolescents found that two doses were needed to produce an adequate immune response.
Študija pri mladostnikih je pokazala, da sta za doseganje zadostnega imunskega odziva potrebna dva odmerka.
The study in CAPS showed a significant and rapid improvement in symptoms, with a fall in average symptom score from 4.5 to 0.8 within 3 days of starting treatment.
V študiji s kriopirinom povezanih sindromov so zabeležili znatno in hitro izboljšanje simptomov, in sicer je povprečna ocena simptomov v treh dneh po začetku zdravljenja padla s 4,5 na 0,8.
The study in children between 2 and 18 years showed that Isentress was safe in children and levels of the medicine obtained in the blood in children were similar to those obtained in adults.
Študija, izvedena pri otrocih, starih od dveh do 18 let, je pokazala, da je zdravilo Isentress zanje varno in da so ravni zdravilne učinkovine v njihovi krvi enake ravnem pri odraslih bolnikih.
The study in children showed similar effectiveness with the combination of Pegasys and ribavirin to that seen in adults treated with Pegasys and ribavirin.
Študija na otrocih je prav tako pokazala podobno učinkovitost s kombinacijo zdravila Pegasys in ribavirina, kot je bila ugotovljena pri odraslih, zdravljenih z isto kombinacijo zdravil.
The study in healthy people showed that when saxagliptin is taken at 2.5 mg twice daily it produces the same levels of active substance in the blood over a 24 hour period as when it is taken at 5 mg once daily.
Študija pri zdravih ljudeh je pokazala, da se pri jemanju 2,5 mg saksagliptina dvakrat na dan v 24 urah tvori enaka raven zdravilne učinkovine v krvi kot pri jemanju 5 mg enkrat na dan.
The study in patients receiving chemotherapy showed that Abseamed was also as effective as Eprex/Erypo when it was injected under the skin.
Študija pri bolnikih, ki so se zdravili s kemoterapijo, je pokazala, da je bilo injiciranje zdravila Abseamed v podkožje enako učinkovito kot zdravilo Eprex/Erypo.
The study in patients receiving chemotherapy showed that Binocrit was also as effective as Eprex/Erypo when it was injected under the skin.
Študija pri bolnikih, ki so se zdravili s kemoterapijo, je pokazala, da je bilo injiciranje zdravila Binocrit v podkožje enako učinkovito kot zdravilo Eprex/Erypo.
The study in patients receiving chemotherapy showed that Epoetin Alfa Hexal was also as effective as Eprex/Erypo when it was injected under the skin.
Študija pri bolnikih, ki so se zdravili s kemoterapijo, je pokazala, da je bilo injiciranje zdravila Epoetin Alfa Hexal v podkožje enako učinkovito kot zdravilo Eprex/Erypo.
The study in patients receiving chemotherapy showed that Silapo brought about similar improvements in haemoglobin levels as those reported in the scientific literature for other epoetins.
V študiji pri bolnikih, ki so prejemali kemoterapijo, so dokazali, da je zdravilo Silapo zagotovilo podobno izboljšanje ravni hemoglobina, kot je opisano v strokovni literaturi za druge epoetine.
The study in patients with chronic kidney failure showed that Abseamed was safe and effective when given under the skin.
Študija, ki je vključevala bolnike s kronično odpovedjo ledvic, je pokazala, da je zdravilo Abseamed varno in učinkovito, kadar se injicira v podkožje.
The study in patients with chronic kidney failure showed that Binocrit was safe and effective when given under the skin.
Študija, ki je vključevala bolnike s kronično odpovedjo ledvic, je pokazala, da je zdravilo Binocrit varno in učinkovito, kadar se injicira v podkožje.
The study in patients with chronic kidney failure showed that Epoetin Alfa Hexal was safe and effective when given under the skin.
Študija, ki je vključevala bolnike s kronično odpovedjo ledvic, je pokazala, da je zdravilo Epoetin Alfa Hexal varno in učinkovito, kadar se injicira v podkožje.
The study in patients with non-valvular atrial fibrillation showed that the proportion of patients who had a stroke or other problems caused by blood clots each year was around 1.5% for patients taking Pradaxa 110 mg (183 patients out of 6,015) and 1.1% for patients taking Pradaxa 150 mg (134 out of
Študija pri bolnikih z atrijsko fibrilacijo, ki ni povezana s srčnimi zaklopkami, je pokazala, da je delež bolnikov, ki so vsako leto imeli kap ali drugo težavo, povezano s krvnimi strdki, okoli 1,5 % (183 od
The study included 423 patients whose disease had recurred or progressed during anti-estrogen therapy (AE subgroup) and 313 patients whose disease had recurred or progressed during aromatase inhibitor therapy (AI subgroup).
V študijo je bilo vključenih 423 bolnic pri katerih je do napredovanja ali ponovitve bolezni prišlo med antiestrogenskim zdravljenjem (AE podskupina) in 313 bolnic, pri katerih je prišlo do napredovanja ali ponovitve med zdravljenjem z zaviralcem aromataze (AI podskupina).
The study included 5 subjects with cirrhosis and 4 were in the Victrelis arm.
Študija je vključevala 5 preiskovancev s cirozo, 4 so bili zdravljeni z zdravilom Victrelis.
The study included 69 patients aged 6 years and above.
V študijo je bilo vključenih 69 bolnikov, starejših od šest let.
The study included 8 subjects with normal renal function (CrCl ≥ 80 mL/min), 8 subjects with mild renal impairment (CrCl 50 mL/min to < 80 mL/min),
V študijo je bilo vključenih 8 oseb z normalno ledvično funkcijo (z očistkom kreatinina ≥ 80 ml/min), 8 oseb z blago okvaro ledvic (z očistkom kreatinina od 50 ml/min do < 80 ml/min), 8 oseb z zmerno okvaro ledvic (z očistkom kreatinina od 30 ml/min do < 50 ml/min), 8 oseb s hudo okvaro ledvic (z očistkom kreatinina
The study included adult patients with confirmed unresectable Stage III or Stage IV melanoma.
V študijo so bili vključeni odrasli bolniki s potrjenim neoperabilnim melanomom v stadiju III ali stadiju IV.
The study included patients whose cancer cells produced high levels of PD-L1 as well as patients whose cancer cells produced low levels of PD-L1.
Študija je vključevala bolnike, pri katerih so rakave celice proizvajale velike količine PD-L1, pa tudi bolnike, pri katerih so rakave celice proizvajale majhne količine PD-L1.
The study included patients with and without cirrhosis as well as patients who had not responded to previous therapy.
Študija je zajela tudi bolnike s cirozo ali brez nje ter bolnike, ki se niso odzvali na predhodno zdravljenje.